Sumitovant Biopharma To Buy Remaining Stake In Myovant In $1.7 Bln Cash Deal
Sumitovant Biopharma Ltd., owned by Sumitomo Pharma Co., Ltd., announced late Sunday a definitive agreement to acquire the remaining stake in Myovant Sciences (MYOV) not already owned by Sumitovant for $27.00 per share in cash. The total transaction value of the deal will be $1.7 billion, and a total company value will be $2.9 billion, both on a fully diluted […]
Read more